No Prognostic Impact of p53 and P-Glycoprotein Expression in Patients with Diffuse Large B-Cell Lymphoma

Rujirojindakul, Pairaya; Aiempanakit, Kumpol; Kayasut, Kanita; Lekhakula, Arnuparp; Sriplung, Hutcha

doi:10.5402/2011/670358

Cited by 7 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, other studies assessing the prognostic signifi cance of P53 overexpression in DLBCL found no association with overall survival (14, 26). Present study, similarly to the Rujirojindakul et al (27), did not demonstrate statistical correlation between p53 expression and age, sex, LDH level, and B symptoms in patients with DLBCL. The fi ndings in our study suggest no relation between P53 expression and survival.…”

Section: Discussionsupporting

confidence: 63%

Immunohistochemical investigation of P16, P53 and Ki-67’s prognostic values in diffuse large B-Cell lymphomas

Baran¹,

Canöz²,

Altuntaş³

et al. 2018

BLL

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 63%

Immunohistochemical investigation of P16, P53 and Ki-67’s prognostic values in diffuse large B-Cell lymphomas

Baran¹,

Canöz²,

Altuntaş³

et al. 2018

BLL

View full text Add to dashboard Cite

show abstract

“…Kramer et al showed that p53 expression was only related to a high tumor burden and was not an independent risk factor for survival in patients with DLBCL [6]. Similarly, in the present study, no significant correlation was found between p53 expression and OS or disease-free survival [5,10,23]. It has been found that p53 expression had no significant effect on OS.…”

Section: Discussionsupporting

confidence: 63%

Prognostic Significance of Bcl-2 and p53 Protein Expressions and Ki67 Proliferative Index in Diffuse Large B-cell Lymphoma

Kucukzeybek¹,

Bener²,

Çallı³

et al. 2013

Tjh

View full text Add to dashboard Cite

Objective: Diffuse large B-cell lymphoma (DLBCL) is a high-grade neoplasm that has heterogeneous properties in clinical, morphological, and immunophenotypic aspects. In the present study the effects of p53, Bcl-2, and Ki67 on prognosis and their relationships with clinical parameters were examined.   Materials and Methods: Thirty-five patients who had been diagnosed with nodally located DLBCL at İzmir Atatürk Training and Research Hospital between January 1999 and June 2006 were included in the study. The Ann Arbor classification system was used to determine the stage of the patients. The patients were evaluated according to age, sex, stage, B symptoms, extranodal involvement, and lactate dehydrogenase (LDH) level as well as immunohistochemically. P53 protein and Bcl-2 oncoprotein expressions and Ki67 proliferation index were assessed immunohistochemically. Results: High Bcl-2 expression was found in 9 patients (25.7%), high p53 expression was found in 10 patients (28.6%), and high Ki67 was observed in 23 patients (65.7%). There was no significant correlation between p53 expression, Bcl-2 expression, or Ki67 proliferation index and age, sex, stage, B symptoms, extranodal involvement, LDH level, and overall survival (p>0.05). We did not find a relationship among p53 expression, Bcl-2 expression, Ki67 proliferation index, and prognosis (p>0.05). There was no significant relationship between overall survival and age, sex, stage, B symptoms, extranodal involvement, or LDH level (p>0.05). Our results revealed that Bcl-2 and p53 protein expressions and Ki67 proliferation index have no effect on overall survival of patients with DLBCL.Conclusion: The prognostic importance of p53 and Bcl-2 protein expressions and Ki67 proliferation index in DLBCL, which has biological and clinical heterogeneity, can be understood in a large series of studies that have subclasses and immunohistochemical markers with optimal cut-off values.

show abstract

“…Some studies have reported that P53 expression is a poor prognostic factor in diffuse large B-cell lymphoma, 24,27 whereas others have shown no prognostic effect. [36][37][38] Multiple factors likely contribute to this inconsistency: different patient cohorts with variable clinical features; diverse biological features such as molecular subtypes; differences in treatment regimens used; and different P53 cutoff levels employed. The prevalence of P53 expression in this patient cohort was 33% using a cutoff of 50% positive cells, similar to that of other studies in the literature in which 20-50% of cases of diffuse large B-cell lymphoma were reported to be positive.…”

Section: Discussionmentioning

confidence: 99%

P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma

et al. 2017

View full text Add to dashboard Cite

In patients with diffuse large B-cell lymphoma, MYC rearrangement (MYC-R), MYC expression, or concurrent expression of MYC and BCL2 is associated with a poorer prognosis. P53 expression also has been shown to confer inferior survival in diffuse large B-cell lymphoma patients, but less is known about the role of P53 expression in those with MYC-R, MYC expression (MYC+), or MYC&BCL2 co-expression (MYC+/BCL2+). We studied P53 expression in 201 patients with untreated de novo diffuse large B-cell lymphoma. Sixty-seven (33%) cases were P53 positive, 56 (28%) had MYC-R (including 17 MYC/BCL2 double hit lymphoma), 86 (45%) were MYC+/BCL2+, and 47 (24%) were positive for both MYC and P53. Compared with patients with P53 negative lymphoma, the P53 positive group had a poorer overall survival (P=0.004). In patients with lymphoma harboring MYC-R, MYC expression or MYC+/BCL2+, P53 expression was associated with a significantly worse overall survival (P<0.0001, P=0.01, and P=0.035, respectively). Patients with lymphoma showing concurrent P53 expression and MYC-R had a worse prognosis compared with patients with either P53 expression or MYC-R alone (P<0.0001). Similarly, P53 enhanced the negative prognostic effect of MYC expression in DLBCL patients. In addition, among patients with lymphoma with concurrent MYC and P53 expression, MYC and BCL2 or BCL2 & P53 expression, those patients with tumors with MYC and P53 expression had the worst overall survival (P=0.005), regardless of BCL2 expression status. Multivariate analysis demonstrated that both MYC-R and P53 expression were independent prognostic factors in this patient cohort. In conclusion, our data suggest that P53 expression and MYC -R or MYC expression have an additive negative prognostic effect in diffuse large B-cell lymphoma patients. Assessment of P53 expression adds additional prognostic information in de novo diffuse large B-cell lymphoma patients, especially in subgroups with MYC-R, MYC expression and MYC and BCL2 double expression.

show abstract

No Prognostic Impact of p53 and P-Glycoprotein Expression in Patients with Diffuse Large B-Cell Lymphoma

Cited by 7 publications

References 21 publications

Immunohistochemical investigation of P16, P53 and Ki-67’s prognostic values in diffuse large B-Cell lymphomas

Immunohistochemical investigation of P16, P53 and Ki-67’s prognostic values in diffuse large B-Cell lymphomas

Prognostic Significance of Bcl-2 and p53 Protein Expressions and Ki67 Proliferative Index in Diffuse Large B-cell Lymphoma

P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma

Contact Info

Product

Resources

About